| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jichun Zhou | Q47681819 |
| P2093 | author name string | Ji Wang | |
| Linbo Wang | |||
| Jianguo Shen | |||
| Shaojie Jiang | |||
| Hanchu Xiong | |||
| Lingmin Xie | |||
| Xinbing Sui | |||
| Benjamin J Seifer | |||
| P2860 | cites work | Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer | Q80163611 |
| Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study | Q81271475 | ||
| Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer | Q81436360 | ||
| Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT) | Q81681821 | ||
| Perioperative chemotherapy for gastric cancer | Q81933458 | ||
| Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy | Q82859282 | ||
| Perioperative chemotherapy for gastric cancer: how should we measure the efficacy? | Q83239566 | ||
| Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients | Q83586221 | ||
| Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer | Q84866623 | ||
| A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker | Q85932400 | ||
| Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors | Q21184033 | ||
| Cancer genome landscapes | Q22242276 | ||
| Complete separation of intracellular and extracellular information in NMR spectra of perfused cells by diffusion-weighted spectroscopy | Q24563568 | ||
| Imaging in the era of molecular oncology | Q24650949 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. | Q28303251 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy | Q30459126 | ||
| Molecular classification of gastric cancer: a new paradigm | Q30500375 | ||
| High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice | Q30939973 | ||
| Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy | Q32061303 | ||
| Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy | Q33903723 | ||
| Personalized oncology through integrative high-throughput sequencing: a pilot study | Q34237470 | ||
| Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. | Q34488692 | ||
| Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial | Q34627996 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers | Q35583933 | ||
| The potential of positron-emission tomography to study anticancer-drug resistance. | Q35788120 | ||
| Neoplasms of the esophagus and stomach | Q35808239 | ||
| Patterns of initial recurrence in completely resected gastric adenocarcinoma | Q35922065 | ||
| How does Lin28 let-7 control development and disease? | Q36204859 | ||
| Molecular classification and correlates in colorectal cancer | Q36329300 | ||
| Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma | Q73501605 | ||
| Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer | Q74604747 | ||
| Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy | Q75405260 | ||
| Japanese classification of gastric carcinoma--2nd English edition--response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria | Q77164025 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma | Q78176506 | ||
| The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer | Q80160506 | ||
| Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer | Q36406800 | ||
| Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis | Q36529266 | ||
| Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond | Q36851802 | ||
| The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer | Q37076617 | ||
| The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies | Q37121679 | ||
| New utility of an old marker: serum low-density lipoprotein predicts histopathological response of neoadjuvant chemotherapy in locally advanced gastric cancer | Q37187705 | ||
| The relationship between Lin28 and the chemotherapy response of gastric cancer | Q37213326 | ||
| Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives | Q37257444 | ||
| Response to preoperative therapy in upper gastrointestinal cancers. | Q37385880 | ||
| MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer | Q37388413 | ||
| Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. | Q37656259 | ||
| New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives | Q37725910 | ||
| Gastric cancer: surgery in 2011. | Q37828465 | ||
| Imaging assessment of tumor response: past, present and future | Q37875082 | ||
| Long-term survival outcomes of advanced gastric cancer patients who achieved a pathological complete response with neoadjuvant chemotherapy: a systematic review of the literature | Q38249890 | ||
| Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil | Q38490073 | ||
| MicroRNAs modulate the chemosensitivity of tumor cells | Q40026480 | ||
| PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial | Q40184245 | ||
| Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin | Q41448414 | ||
| Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer | Q43135271 | ||
| How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care | Q43494882 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features | Q43688177 | ||
| Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment | Q43774657 | ||
| Whole-body PET with FDG for the diagnosis of recurrent gastric cancer | Q43933728 | ||
| Preoperative treatment and surgery in gastric cancer: friends or foes? | Q43971937 | ||
| Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome | Q44019896 | ||
| Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. | Q44298526 | ||
| Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients | Q44544185 | ||
| Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy | Q44595957 | ||
| Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study | Q44603561 | ||
| Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial | Q44691627 | ||
| Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy | Q45199676 | ||
| Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. | Q45279369 | ||
| Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). | Q46049845 | ||
| Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients | Q46443635 | ||
| Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer | Q46650523 | ||
| Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer | Q46755986 | ||
| Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification | Q46770169 | ||
| Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis | Q46897723 | ||
| The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. | Q51820596 | ||
| Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. | Q53076599 | ||
| Preoperative Chemoradiation in an Era of Suboptimal Clinical Staging. | Q53281431 | ||
| MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. | Q53518186 | ||
| Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. | Q53634486 | ||
| Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. | Q55043363 | ||
| NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. | Q55462394 | ||
| Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy | Q56770211 | ||
| Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer? | Q57846038 | ||
| Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations | Q72458494 | ||
| Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy | Q73258223 | ||
| Recurrence following curative resection for gastric carcinoma | Q73442414 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic variation | Q349856 |
| stomach neoplasm | Q4335552 | ||
| tumor biomarker | Q66205818 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 30477-30494 | |
| P577 | publication date | 2017-05-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer | |
| P478 | volume | 8 |
| Q91714550 | A Personalised Dietary Approach-A Way Forward to Manage Nutrient Deficiency, Effects of the Western Diet, and Food Intolerances in Inflammatory Bowel Disease |
| Q47097207 | DNA Methylation-Mediated Silencing of Regenerating Protein 1 Alpha (REG1A) Affects Gastric Cancer Prognosis. |
| Q48572985 | Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma |
| Q50047894 | LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3β signaling |
| Q54122768 | REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through PI3K/Akt signaling pathway. |
| Q92683156 | The E2F3/miR-125a/DKK3 regulatory axis promotes the development and progression of gastric cancer |
Search more.